Full-Time

Senior Associate/ Manager Payroll & Benefits

Payroll & Benefits

Superluminal Medicines

Superluminal Medicines

51-200 employees

ML-driven design of candidate small molecules

No salary listed

Boston, MA, USA

In Person

Bachelor's

Category
People & HR (1)
Required Skills
NetSuite
Human Resources Information System (HRIS)
Excel/Numbers/Sheets

Get referred to Superluminal Medicines

See people who can refer or advise you

Requirements
  • Bachelor’s degree in Accounting, Finance, Human Resources, Business Administration, or a related field; or equivalent professional experience.
  • 5+ years of progressive payroll and benefits administration experience, with at least 2 years in a publicly traded company environment.
  • Demonstrated hands-on experience administering equity compensation plans (ISOs, NQSOs, and/or RSUs) and processing related payroll tax withholding and reporting.
  • Direct involvement in proxy statement preparation or review.
  • Working knowledge of SOX internal controls as they apply to payroll and HR data/processes.
  • Proficiency with a major payroll/HRIS platform, Paylocity a plus.
  • Experience with an equity management platform, Carta is a plus.
  • Advanced Microsoft Excel skills (pivot tables, VLOOKUP/XLOOKUP, data validation, etc).
  • Familiarity with general ledger and ERP systems, NetSuite a plus.
  • Excellent verbal and written communication skills.
Responsibilities
  • Process multi-state, full-cycle payroll (semi-monthly) with accuracy and timeliness for all employees.
  • Reconcile payroll registers, general ledger entries, and payroll-related balance sheet accounts.
  • Ensure compliance with federal, state, and local wage and hour laws, tax regulations, and garnishment orders.
  • Partner with accounting on payroll accruals, journal entries, month-end close activities, ad hoc reporting, and system integrations.
  • Administer health, dental, vision, life, disability, FSA/HSA, and 401(k) plans including onboarding, open enrollment, qualifying life events, and day-to-day employee inquiries.
  • Coordinate with HR, benefits brokers, and carriers on plan changes, renewals, billing reconciliation, and claims escalations.
  • Manage COBRA administration, ACA reporting (1094-C/1095-C), annual non-discrimination testing, as well as other reporting as assigned.
  • Support leave of absence processes (FMLA, state leaves, personal leave).
  • Develop, update, and communicate benefits and leave policies while serving as the primary resource for employee inquiries, issue resolution, and interpretation of plan and policy provisions.
  • Maintain accurate and up-to-date employee records in the HRIS, including new hires, terminations, transfers, promotions, compensation changes, and personal data updates.
  • Process employment verifications, unemployment claims, and HR-related correspondence.
  • Support HR compliance activities including I-9 administration, E-Verify, EEO-1, and applicable state HR filings.
  • Respond to employee inquiries regarding HR policies, procedures, and programs; escalate complex issues appropriately.
  • Support the administration of compensation change workflows, and merit increase processing in the HRIS.
  • Coordinate and facilitate the new hire onboarding record keeping, including pre-boarding paperwork, HRIS setup, benefits enrollment, and payroll activation.
  • Administer offboarding processes including final pay calculations, benefits termination, equity notifications, equipment retrieval coordination, and exit interview scheduling.
  • Maintain and continuously improve onboarding and offboarding checklists to reflect current policies, systems, and compliance requirements.
  • Serve as a functional administrator for the HRIS and payroll platform; manage configuration, integrations, and audits.
  • Generate and analyze standard and ad-hoc compensation, benefits, and headcount reports for leadership and Finance.
  • Identify and implement process improvements to increase efficiency, reduce error risk, and strengthen internal controls.
  • Train managers and employees on self-service tools, equity portals, and benefits platforms.
  • Work with the current stock plan administrator to execute equity award programs, including ISOs/NQSOs.
  • Maintain equity data integrity between the equity management platform and the HRIS/payroll system .
  • Support equity expense calculations, JEs, and Black-Scholes inputs
  • Calculate and withhold applicable taxes on equity events (vesting/exercises) and ensure accurate W-2 and supplemental income reporting.
Desired Qualifications
  • CPP Certified Payroll Professional (APA) - Preferred and/or willing to attain
  • Certified Equity Professional - Preferred (desire to obtain preferred)
Superluminal Medicines

Superluminal Medicines

View

Superluminal Medicines develops small-molecule drug discovery solutions by combining deep biology, chemistry, and machine learning. It creates candidate-ready compounds with high speed and accuracy, using a proprietary big data platform and predictive design models to model protein shapes and design selective compounds that induce precise structural changes for therapeutic effects. The company collaborates with pharmaceutical and biotech firms, licensing its technology and pursuing milestone-based payments, rather than selling products outright. This partnership-centric model helps clients accelerate their drug discovery programs in a highly competitive market. The company aims to shorten the path from target to clinical candidate by delivering well-characterized, selective small molecules efficiently.

Company Size

51-200

Company Stage

Series A

Total Funding

$153M

Headquarters

Boston, Massachusetts

Founded

2023

Get referred to Superluminal Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Lilly's February 2026 update reaffirmed up to $1.3B in payments.
  • Superluminal expects an IND submission in late 2026 for obesity.
  • RA Capital, Insight, NVentures, Catalio, and Lilly funded the $120M Series A.

What critics are saying

  • Lilly gets exclusive rights, so Superluminal loses downstream economics.
  • The lead obesity asset still needs 2026 human data after IND filing.
  • A failed MC4R program would crush platform credibility and future partnering.

What makes Superluminal Medicines unique

  • Superluminal combines protein dynamics, structural biology, and ML on GPCRs.
  • Lilly backed the 2024 Series A and signed a 2025 $1.3B pact.
  • Its lead MC4R obesity program entered IND-enabling studies in July 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Flexible Work Hours

Hybrid Work Options

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Wellness Program

Mental Health Support

Gym Membership

Conference Attendance Budget

Professional Development Budget

Stock Options

Company Equity

401(k) Retirement Plan

401(k) Company Match

Phone/Internet Stipend

Home Office Stipend

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Parental Leave

Relocation Assistance

Employee Referral Bonus

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Training Programs

Tuition Reimbursement

Meal Benefits

Commuter Benefits

Pet Insurance

Legal Services

Employee Discounts

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

31%

1 year growth

31%

2 year growth

31%
The Pharma Letter
Aug 15th, 2025
Lilly and Superluminal work on GPCR drugs for cardiometabolic diseases

Eli Lilly (NYSE: LLY) has entered into a collaboration with Boston-based Superluminal Medicines to develop small-molecule therapies for undisclosed G protein-coupled receptor (GPCR) targets linked to cardiometabolic diseases and obesity.

Fierce Biotech
Aug 14th, 2025
Superluminal secures $1.3B pact with backer Lilly to develop cardiometabolic, obesity drugs

Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G protein-coupled receptor biotech. | Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G protein-coupled receptor biotech.

BioWorld
Aug 14th, 2025
Superluminal, Lilly in $1.3B Deal

Superluminal Medicines Inc. has entered a collaboration with Eli Lilly and Co. in a deal worth up to $1.3 billion. The partnership aims to develop therapies for cardiometabolic diseases and obesity by targeting undisclosed G protein-coupled receptors. The deal includes up-front and near-term investments, an equity investment, development and commercial milestones, and tiered royalties on net sales.

BioWorld
Aug 14th, 2025
Superluminal joins a $1.3B deal with series A backer Lilly

Superluminal Medicines Inc. and Eli Lilly and Co. are collaborating in a deal to develop cardiometabolic disease and obesity therapies by aiming at undisclosed G protein-coupled receptor targets.

FinSMEs
Sep 9th, 2024
Superluminal Medicines Closes $120M Series A Funding

Superluminal Medicines, a Boston, MA-based company that uses generative biology, chemistry and machine learning approaches to create medicines, raised $120M in Series A funding